That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas
By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm
Researchers in Dallas are investigating the potential of weight loss medications, specifically a drug called tirzepatide, as a novel approach to reducing the risk of breast cancer recurrence in women who are overweight or obese. This clinical trial, led by Dr. Joyce O’Shaughnessy, aims to determine if these popular drugs, known for promoting significant weight loss, can help prevent cancer from returning. The study is targeting women with a high risk of recurrence, identified through specific criteria including a BMI of 27 or higher and the presence of tumor DNA in their bloodstream. The rationale behind this research is that weight loss can decrease inflammation, which is thought to be a contributing factor to the link between obesity and cancer. If successful, this trial could establish these weight loss drugs as valuable tools for cancer prevention in survivors.
There are now 132 studies for Breast Cancer and obesity going on in the United States today. Check out the list at NIH ClinicalTrials.gov.
Audio Overview (Google NotebookLM)
(4 minutes 9 seconds)
